Cargando…
Persistent Post–COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment
Rationale: The natural history of recovery from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unknown. Because fibrosis with persistent physiological deficit is a previously described feature of patients recovering from similar coronaviruses, treatment represents an early oppo...
Autores principales: | Myall, Katherine Jane, Mukherjee, Bhashkar, Castanheira, Ana Margarida, Lam, Jodie L., Benedetti, Giulia, Mak, Sze Mun, Preston, Rebecca, Thillai, Muhunthan, Dewar, Amy, Molyneaux, Philip L., West, Alex G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086530/ https://www.ncbi.nlm.nih.gov/pubmed/33433263 http://dx.doi.org/10.1513/AnnalsATS.202008-1002OC |
Ejemplares similares
-
The burden of progressive fibrotic interstitial lung disease across the UK
por: Simpson, Thomas, et al.
Publicado: (2021) -
Quality improvement in Respiratory Medicine: Designing and implementing a bronchoscopy checklist at Southend University Hospital
por: Thillai, Muhunthan, et al.
Publicado: (2013) -
How COVID-19 interacts with interstitial lung disease
por: Myall, Katherine J., et al.
Publicado: (2022) -
Use of Corticosteroid in Persistent Post–COVID-19 Interstitial Lung Disease
por: Khaw, Chuen R., et al.
Publicado: (2021) -
Reply: A Role for Steroids in COVID-19–associated Pneumonitis at Six-Week Follow-Up?
por: Myall, Katherine J., et al.
Publicado: (2021)